Ada­gio of­fers first peek at Covid-19 an­ti­body da­ta, with pre­ven­ta­tive num­bers that may ri­val mR­NA vac­cines

Till­man Gern­gross cer­tain­ly wasn’t the first to tack­le Covid-19 an­ti­bod­ies, but he has rea­son to be­lieve he and his team at Ada­gio could be the best. Now, we’re get­ting a first peek at hu­man pre­ven­ta­tive da­ta for Ada­gio’s lead an­ti­body, and it looks up to par with the best of the vac­cines.

Now, Ada­gio is churn­ing out ear­ly da­ta from that Phase I test show­ing a sin­gle dose of an­ti­body ADG20 of­fered broad­ly neu­tral­iz­ing ac­tiv­i­ty in healthy vol­un­teers com­pa­ra­ble to peak titers re­port­ed from the mR­NA vac­cines and could of­fer pro­tec­tion for up to 12 months, the biotech said Wednes­day. There were no hard num­bers im­me­di­ate­ly avail­able.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER